NC-1 treatment further decreased baseline CD69 surface levels, completely abrogated its upregulation following IgM activation, decreased CLL cells migration toward SDF-1 and overcame stromal anti-apoptotic protection. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.